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How ATP is utilized by heat shock protein 90 (Hsp90)
has been the subject of some controversy [1–3]. Subse-
quent structural, biochemical and cellular studies [4–7]
demonstrated unequivocally that Hsp90 binds and
hydrolyses ATP in vitro, and its ability to do so is
essential to its role as a molecular chaperone in vivo.
Despite general acceptance of Hsp90 as an ATP-
dependent molecular machine [8], the detailed mecha-
nism by which Hsp90 hydrolyses ATP, and the
coupling of this activity to conformational changes in
the Hsp90 dimer, remain controversial. Studies of
yeast Hsp90 have deﬁned a coherent ATPase-coupled
conformational cycle in which ATP binding and
hydrolysis are linked to the opening and closing of a
molecular clamp involving transient ATP-dependent
association of the N-terminal domains in the Hsp90
dimer [9–12]. However, no cooperation between the
N-terminal domains has been seen for human Hsp90,
suggesting that they operate as independent units with
no functional requirement for association [13].
While it is possible that yeast and human Hsp90s
operate by different mechanisms, their high overall
sequence identity (61.5%), their near-complete conser-
vation of all residues involved in ATP transactions,
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The conformationally coupled mechanism by which ATP is utilized by
yeast Hsp90 is now well characterized. In contrast, ATP utilization by
human Hsp90s is less well studied, and appears to operate differently. To
resolve these conﬂicting models, we have conducted a side-by-side biochem-
ical analysis in a series of mutant yeast and human Hsp90s that have been
both mechanistically and structurally characterized with regard to the crys-
tal structure of the yeast Hsp90 protein. We show that each monomer of
the human Hsp90 dimer is mutually dependent on the other for ATPase
activity. Fluorescence studies conﬁrmed that the N-terminal domains of
Hsp90b come into close association with each other. Mutations that
directly affect the conformational dynamics of the ATP-lid segment had
marked effects, with T31I (yeast T22I) and A116N (yeast A107N) stimulat-
ing, and T110I (yeast T101I) inhibiting, human and yeast ATPase activity
to similar extents, showing that ATP-dependent lid closure is a key rate-
determining step in both systems. Mutation of residues implicated in N-ter-
minal dimerization of yeast Hsp90 (L15R and L18R in yeast, L24R and
L27R in humans) signiﬁcantly reduced the ATPase activity of yeast and
human Hsp90s, showing that ATP-dependent association of the N-terminal
domains in the Hsp90 dimer is also essential in both systems. Furthermore,
cross-linking studies of the hyper-active yeast A107N and human A116N
ATP-lid mutants showed enhanced dimerization, suggesting that N-termi-
nal association is a direct consequence of ATP binding and lid closure in
both systems.
Abbreviations
AMPPNP or PNP, adenosine 5¢-(b,c-imino)-triphospahte; DMS, dimethyl suberimidate; FRET, ﬂuorescence resonance energy transfer; Grp94,
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the yeast and human Hsp90a N-terminal domains are
virtually identical make this unlikely [14,15]. In an
attempt to resolve this issue, we have conducted a
side-by-side biochemical analysis of a matched series
of yeast and human Hsp90 proteins mutated at resi-
dues implicated in the ATP-coupled conformational
mechanism deduced from the yeast studies, the mecha-
nistic and structural consequences of which can be
understood in the context of the crystal structure of
full-length yeast Hsp90 [9]. These studies suggest an
essentially identical set of conformational changes that
accompany the ATPase cycle in both species.
Results
C-terminal truncation mutants of Hsp90b have a
reduced ATPase activity
We have previously shown that removal of the C-ter-
minal dimerization domain of yeast Hsp90 greatly
reduces its ATPase activity [10]. Although the trun-
cated protein contains all the catalytic machinery nec-
essary to hydrolyse ATP, the absence of the
constitutive dimerization interface makes ATP-depen-
dent N-terminal association less efﬁcient, showing that
N-terminal association is required for ATP turnover.
When we measured the ATPase activity of a similarly
C-terminally truncated human Hsp90b construct (resi-
dues 1–615), we found that its ATPase activity was
also drastically reduced compared to the wild-type
(Fig. 1A), consistent with a previous study [13]. Thus
C-terminal truncation in human Hsp90b and in yeast
Hsp90 drastically reduces both their ATPase activities,
suggesting that it affects a common mechanistic fea-
ture, and this is fully consistent with the assumption
that N-terminal dimerization and therefore the ATPase
activity of Hsp90b are assisted by physical association
of the two molecules within each Hsp90 dimer at their
C-termini.
Mutations affecting ATP-lid closure in yeast and
human Hsp90 suggest a common mechanism for
the hydrolysis of ATP
Work using yeast Hsp90 has shown that the ATPase
activity is dependent on transient association of the
N-terminal nucleotide-binding domains within the
Hsp90 dimer [10]. Binding of ATP to the yeast Hsp90
N-terminal domain promotes remodelling and closure
of a segment of polypeptide (residues 94–123 in yeast,
equivalent to 103–132 in human Hsp90b) that forms a
‘lid’ over the nucleotide-binding site [9]. Closure of the
ATP lid in each Hsp90 monomer exposes hydrophobic
surfaces that can interact with each other within the
dimer and thus stabilize N-terminal association.
We have previously characterized a series of muta-
tions of yeast Hsp90 that alter ATPase activity by
changing the dynamics of the coupled lid-closure and
N-terminal-association processes [10] (Fig. 2). The
A107N mutation promotes N-terminal association and
greatly enhances ATPase activity by stabilizing the
ATP lid in the closed conformation via formation of
an additional polar interaction with Tyr47. The T22I
mutation has a similar effect on N-terminal dimeriza-
tion and ATP hydrolysis by increasing the hydropho-
bicity of the N-terminal dimerization interface (Fig. 2).
In contrast, the increased hydrophobicity of the under-
side of the ATP lid resulting from the T101I mutation
stabilizes the lid in its open state, and therefore
decreases ATPase activity. We investigated the effect
of the equivalent mutations in the N-terminal domain
of Hsp90b on its ATPase activity. Consistent with the
previous observations in yeast Hsp90, the T31I (yeast
T22I) and A116N (yeast A107N) mutations both
enhanced the ATPase activity of Hsp90b, while the
T110I mutation (yeast T101I) drastically reduced it
(Fig. 1D). The equivalent mutations in human and
yeast Hsp90 therefore affect ATPase activity in the
same way, suggesting that they affect mechanistic
features common to both, namely ATP-lid closure and
N-terminal association.
The monomers of the Hsp90 dimer are mutually
dependent on each other for ATPase activity
The results so far are consistent with the suggestion
that human Hsp90 undergoes an ATP-coupled confor-
mational change that leads to dimerization of its
N-terminal domains. However, a direct dependence of
one monomer of Hsp90 on the other monomer has
not yet been demonstrated. In order to show this, we
formed heterodimers (A116N–T110I and A116N–
L24R), as previously described [16], by mixing 2 lm
human Hsp90b carrying the A116N mutation with up
to a tenfold molar excess of the T110I mutant and a
ﬁvefold molar excess of the L24R mutant. Results pre-
sented below suggest that the L24R mutant prevents
N-terminal dimerization. Consequently, with increasing
molar ratios of the T110I and L24R mutants, relative
to the ﬁxed amount of A116N, we expect the concen-
tration of the A116N–T110I and A116N–L24R hetero-
dimers to increase relative to free A116N homodimer.
Thus the ATPase activity that is detected is increas-
ingly due to heterodimers rather than free homodimers
of A116N (the free homodimers of L24R and T110I
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bution is low due to their inherently low ATPase activ-
ity). If the activity of each monomer is independent of
its dimeric partner, the activity of A116N would be
unaffected by the T110I or L24R mutation in the adja-
cent monomer. Consequently, we would detect an
activity that is the sum for the A116N and T110I or
L24R activities. However, if the activity of A116N
were dependent on its dimeric partner, we would see a
decrease in the ability of the A116N monomer to
hydrolyse ATP, and the total activity detected would
decrease. The results in Fig. 1C show that the T110I
and L24R mutations did indeed decrease the overall
ATPase activity detected, which suggests that they
affect the ability of A116N to hydrolyse ATP. To test
the possibility that the L24R and T110I mutants affect
the ATPase by some non-speciﬁc mechanism, we also
added a tenfold molar excess of human Hsp90b to
2 lm A116N. As this experiment utilizes two molecules
that are both substantially active, the effect on the
overall ATPase activity should be to approach that of
Hsp90b, since it is not only in excess, but less active
and would limit the ATPase activity of the more active
A116N, as seen with the A116N–L24R and A116N–
T110I heterodimers. We also added a tenfold molar
excess of Hsp90b to 2 lm yeast Hsp90, which are unli-
kely to heterodimerize because their C-terminal dimer-
ization interfaces are not completely identical.
Consequently, we expect to see an activity that is the
sum of the two separate activities (Hsp90b + yeast
Hsp90). The results shown in Fig. 1D are consistent
with this. The ATPase activity of the A116N⁄Hsp90b
mixture was slightly higher than that of Hsp90b alone,
but less than the combined sum of the A116N and
A  B 
C  D 
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Fig. 1. ATPase activity of yeast Hsp90 and
human Hsp90b. The relative ATPase activi-
ties for (A) the C-terminal truncation mutant
Hsp90b N615, (B) the Hsp90b mutations
affecting ATP-lid conformation, (C) the
A116N–T110I and A116N–L24R heterodimer
experiments, (D) the Hsp90b–A116N and
Hsp90b–yeast Hsp90 heterodimer experi-
ments, (E) mutations directly affecting N-ter-
minal dimerization of yeast Hsp90, and (F)
mutations directly affecting N-terminal
dimerization of human Hsp90b. The molar
concentrations of the Hsp90 constructs
used are shown. Assays were performed at
37  C for 15–60 min. Geldanamycin at a
concentration of 30–60 lM was used to
obtain the baseline activity of contaminating
background ATPase. For the Hsp90 hetero-
dimer assays, 2 lM of A116N was used
with increasing amounts of T110I, L24R,
Hsp90b and yeast Hsp90, and the relative
molar concentration used is shown above
the corresponding activity. All assays were
performed at least three times, and the kcat
values for yeast and human Hsp90 were
0.91 and 0.056⁄min, respectively, at 37  C.
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effect on the ATPase activity of human Hsp90, sug-
gesting that inhibition of A116N is unlikely to be due
to non-speciﬁc effects on the A116N protein (Fig. 1D).
In conclusion, the results suggest that the monomers
of the Hsp90 dimer are mutually dependent on each
other for the hydrolysis of ATP. Such cooperation
between the monomers of human Hsp90 is consistent
with association of the N-terminal domains, as seen
with yeast Hsp90.
AMPPNP promotes N-terminal dimerization
The ATPase activity results of the heterodimeric
A116N–T110I and A116N–L24R experiments suggest
that the N-terminal domains are dependent on each
other for their ATPase activity. We used ﬂuorescence
resonance energy transfer (FRET) to investigate the
conformation of Hsp90 as previously described for the
yeast protein [10]. When excited and in close contact,
pyrene molecules display a marked alteration in ﬂuo-
rescence emission at 450–500 nm (excimer formation).
A structural analysis revealed that human Hsp90b con-
tains six cysteine residues, four of which are buried
and cannot be labelled without denaturing the protein.
The ﬁfth is present within the C-terminal domain, but
in a position that would prevent pyrene from interact-
ing with a second pyrene at the equivalent position on
the adjacent monomer. The sixth cysteine residue
(Cys366) is present within the middle domain. Poten-
tially, this residue would allow excimer formation if
labelled with pyrene. We therefore mutated this surface
cysteine to alanine, and introduced a new cysteine resi-
due by mutating Glu20 (E11C in yeast Hsp90) in the
A116N background. The A116N mutant was chosen
as this would maximize the excimer signal that could
be generated, which we expected to be low due to the
lower inherent ATPase activity of Hsp90b. The ﬂuores-
cent emission spectrum of labelled E20C-A116N-
C336A, either in the presence of ADP or AMPPNP,
showed signiﬁcant excimer formation compared to
control protein (A116N-C336A) subjected to the
pyrene modiﬁcation procedure (Fig. 3A), as previously
seen with E11C pyrene-labelled yeast Hsp90. However,
in contrast to the control C366A-A116N protein, the
excimer signal for the E20C-C336A-A116N pyrene-
labelled protein was enhanced in the presence of AMP-
PNP compared to ADP (Fig. 3B), thus conﬁrming that
AMPPNP promotes a closer association of the N-ter-
minal domains. Subsequently, we demonstrated that
heterodimer formation between the pyrene-labelled
E20C-C366A-A116N mutant protein and control pro-
tein (C366A-A116N) in the presence of AMPPNP
resulted in a decrease in excimer ﬂuorescence (Fig. 3C).
Thus, it appears that heterodimer formation decreases
interactions between pyrene-labelled E20Cs on the two
monomers, as the control protein (C366A-A116N)
lacks one of the speciﬁc pyrene labels at position 20.
The results, as a whole, suggest that, as for the yeast
protein, human Hsp90b also undergoes N-terminal
dimerization.
N-terminal dimerization is essential for ATPase
activity in yeast and human Hsp90
The ATP-lid mutations and the mutual dependency of
the monomers of dimeric Hsp90b for ATPase activity
suggest that the human protein undergoes N-terminal
dimerization, in common with yeast Hsp90. Mutations
in yeast Hsp90 that directly inhibit N-terminal dimer-
ization, and therefore ATPase activity, have not been
previously described. Analysis of the structure of the
yeast Hsp90–AMPPNP–Sba1 complex [9] suggested
that Leu15 and Leu18, which play no direct catalytic
role in the hydrolysis of ATP, are important for N-ter-
minal dimerization, as they form part of the hydropho-
bic core for this interaction (Fig. 4A). We therefore
mutated Leu15 and Leu18 to either alanine or argi-
nine, and determined the effects of these mutations on
ATPase activity of Hsp90, which is a measure of
N-terminal dimerization. We found that the L15A and
Fig. 2. Molecular interactions of yeast ATP-lid mutations. The ATP
lid in its closed state brings the A107N mutation in close proximity
to Tyr47, with which it interacts. This stabilizes the ATP lid in the
closed state. In contrast, Thr101 is on the underside of the ATP lid
in its open state (shown in turquoise). An isoleucine at this position
increases hydrophobic interactions with similar residues in its vicin-
ity. Thr22 in the closed state contacts the catalytic loop (shown in
magenta), interacting with Leu378 of the neighbouring middle
domain of the Hsp90 dimer. An isoleucine at this position would
increase the hydrophobic nature of the interaction with Leu378 and
would favour N-terminal dimerization.
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turally, had no inhibitory effect on the ATPase activity
of yeast Hsp90 (157 and 103% activity, respectively,
relative to wild-type yeast Hsp90; Fig. 1E). In fact, the
L15A mutation activated the ATPase activity of yeast
Hsp90. However, L18R, and in particular the L15R
mutation, which prevent formation of the dimer inter-
face, signiﬁcantly reduced ATPase activity (42 and
9.5% activity, respectively, relative to wild-type yeast
Hsp90; Fig. 1E). This suggests that N-terminal dimer-
ization is compromised by both the L15R and L18R
mutations, and conﬁrms that the ATPase activity of
yeast Hsp90 is dependent on close association of the
N-terminal domains. Having identiﬁed mutations in
yeast Hsp90 that directly inhibit N-terminal dimeriza-
tion, we created the equivalent mutant forms of
Hsp90b and evaluated their ability to N-terminally
dimerize by determining their ATPase activity. We
found that the ATPase activity of L24A was almost
identical to that of wild-type Hsp90b (101% activity
relative to wild-type Hsp90b; Fig. 1F), whereas the
L27A mutation showed a somewhat reduced activity
because Alanine at this position disfavors dimerization
(30% activity relative to wild-type Hsp90b; Fig. 1F).
Consistent with N-terminal dimerization, the L24R
and L27R mutations also showed a reduction in
ATPase activity (6.2 and 17% activity, respectively,
relative to wild-type Hsp90b; Fig. 1F). Although it is
possible to envisage other means by which these
mutants might affect the ATPase activity of human
Hsp90, these results are nonetheless consistent with the
idea that the ATPase activity of human Hsp90b, like
that of yeast Hsp90, is dependent on N-terminal
dimerization. It is noted that the L15A mutation acti-
vated the ATPase activity of yeast Hsp90, whereas the
equivalent mutation (L24A) in Hsp90b had very little
effect. Similarly, the L18A mutation had a less severe
effect on the ATPase activity of yeast Hsp90 than the
equivalent (L27A) mutation of Hsp90b. These slight
differences are to be expected in such a complex sys-
tem, and probably reﬂect differences in the overall
dynamics and stability of the dimerization process.
Nonetheless, we have identiﬁed mutations in yeast
(L15R and L18R) that are consistent with the disrup-
tion of N-terminal dimerization. Furthermore, when
the equivalent mutations are made in Hsp90b (L24R
and L27R), its ATPase activity is also disrupted, sug-
gesting that it too undergoes N-terminal dimerization.
We next tested the binding of AMPPNP to the L15R
and L24R mutant Hsp90s to exclude the possibility
that the mutations inhibited the binding of ATP.
We found that neither mutation inhibited binding
of the non-hydrolysable ATP analogue, AMPPNP
A
B
C
Fig. 3. N-terminal interactions of pyrene-labelled cysteine mutants.
(A) Speciﬁc excimer ﬂuorescence signals normalized for the
pyrene-labelled E20C-A116N-C366A (E20C) protein and pyrene-
treated control protein A116N-C366A (WT) in the presence of either
AMPPNP (PNP) or ADP. Spectra were obtained for three separate
labelling reactions, and the results of a typical experiment are
shown. The results show that the WT signal is similar in the pres-
ence of either AMPPNP or ADP, whereas the mutant speciﬁcally
labelled at position E20C shows an increase in excimer ﬂuores-
cence in the presence of AMPPNP over that with ADP. (B) Speciﬁc
excimer ﬂuorescence signals for the E20C mutant and the control
protein (WT) in the presence of AMPPNP, corrected for the signal
in the presence of ADP. The traces are the mean of three separate
experiments. The E20C mutant displays enhanced excimer ﬂuores-
cence relative to the control protein. (C) Speciﬁc excimer formation
of the labelled protein E20C in the presence of increasing amounts
of WT control protein. The WT protein speciﬁcally reduces excimer
ﬂuorescence, indicating that it forms heterodimers with the E20C
protein and thus reduces interactions between the pyrene-labelled
E20Cs of two monomers upon AMPPNP binding. Excimer ﬂuores-
cence occurs in the wavelength of 450–500 nm.
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afﬁnity for AMPPNP (yeast Hsp90,
Kd = 103 ± 4.4 lm; L15R, Kd = 12 ± 4.7 lm;
human Hsp90b, Kd = 177 ± 3.3lm;L 2 4 R ,
Kd = 22.0 ± 0.83 lm) that probably reﬂects a more
accessible active site due to the mutations shifting the
equilibrium away from the closed state.
AMPPNP promotes N-terminal dimerization of
Hsp90b
The results so far suggest that human Hsp90 under-
goes an ATP-coupled conformational change that
leads to dimerization of its N-terminal domains. We
investigated whether the non-hydrolysable ATP ana-
logue, AMPPNP, could drive N-terminal dimerization
of the yeast and human Hsp90s by using the
cross-linking reagent dimethyl suberimidate (DMS) to
capture the transient N-terminally dimerized state. The
results in Fig. 5A–D and Fig. S1 show that AMPPNP
promotes the enhancement of cross-linked dimers, rela-
tive to ADP, thus suggesting that AMPPNP binding
leads to N-terminal dimerization in both the human
and yeast proteins. It should be noted that, as Hsp90
is inherently dimeric, both ADP and AMPPNP allow
formation of cross-linked dimers; however, there is a
consistent enhancement of cross-linked dimer forma-
tion in the presence of AMPPNP. In the presence of
AMPPNP, the band with the highest molecular mass,
representing cross-linked dimer species, was more
abundant than in the presence of ADP for both the
yeast and human Hsp90s (Fig. 5A–D and Fig. S1).
This indicates that the ADP– and AMPPNP–Hsp90
complexes are structurally distinct. Thus, it appears
BC
DE
A
Fig. 4. Part of the N-terminal dimerization
interface of Hsp90 and binding of AMPPNP
to N-terminal dimerization mutants. (A) The
two chains of the Hsp90 dimer are shown
in green and turquoise. Two hydrophobic
residues (Leu15 and Leu18) were identiﬁed
as potential sites for mutation in order to
disrupt N-terminal association. Mutations to
alanine can be easily accommodated at
these sites, whereas a change to arginine is
likely to be disruptive. (B–E) AMPPNP bind-
ing to yeast Hsp90 (B), human Hsp90b (C),
the yeast L15R mutant (D) and the human
L24R mutant (E) by isothermal titration
calorimetry.
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formed in the preference of AMPPNP (Fig. 5C and
Fig. S1), which promotes the N-terminally dimerized
state, while the faster running bands result mainly
from the inherently dimerized open state. However, it
should be noted that the cross-links that are formed in
the presence of ADP are also formed in the closed
state with AMPPNP. Thus, the amino acid residues
that were cross-linked in the ADP experiment are
close enough in the AMPPNP state to be subject to
cross-linking. Whether the slowly migrating band
results from a single cross-link and the location of
such cross-links is unknown. N-terminal dimerization
would result in not only the N-terminal domains asso-
ciating, but also in the middle domains coming into
closer contact. Thus potentially many cross-links are
possible, and their location need not necessarily be lim-
ited to the N-terminal domains. However, in order to
conﬁrm that AMPPNP drives N-terminal dimerization
and allows formation of the slowly migrating band, we
used geldanamycin, an Hsp90 inhibitor known to bind
to the ATP-binding pocket of Hsp90 and prevent
A 
BC
m
Fig. 6. Cross-linking reactions with mutations of yeast Hsp90 and
Hsp90b. Cross-linking with DMS in the presence of AMPPNP for
(A) yeast Hsp90 and the L15A and L15R mutations for 15 min, or
(B) human Hsp90b and the T110I, A116N, L24A and L24R muta-
tions for 60 min, or (C) the L24R-A116N mutation of Hsp90b for
60 min. The arrow shows the position of the slowly migrating
cross-linked species, which are favourably formed with the A116N
mutant. Proteins for cross-linking were diluted to a ﬁnal concentra-
tion of 0.25–0.5 mgÆmL
)1 in 100 mM Hepes, pH 8.5, 150 mM KCl
and 5 mM MgCl2, with either 5 mM ADP-Mg
2+ or AMPPNP-Mg
2.
For yeast Hsp90 and Hsp90b reactions, 7.5 and 3.75 M excesses of
DMS, respectively, were used relative to the molar concentration
of Hsp90 lysine amino acid residues. The N-terminal dimerization
mutations, L15R (yeast) and L24R (human), as well as T110I (T101I
in yeast) reduce formation of the slowly migrating cross-linked spe-
cies (shown by the arrow), which is consistent with the ATP-lid
model. All cross-linking assays were performed in triplicate, and
typical results are shown.
CD
AB
mm
Fig. 5. Cross-linking reactions with yeast Hsp90 and Hsp90b.
Cross-linking with DMS in the presence of ADP or AMPPNP for (A)
yeast Hsp90 and (B) human Hsp90b for 15 min, or (C) yeast and
human Hsp90 for 60 min. (D) Inhibition of cross-linking of yeast and
human Hsp90s by geldanamycin. All cross-linking assays were per-
formed in triplicate, and typical results are shown. Proteins for
cross-linking were diluted to a ﬁnal concentration of 0.25–
0.5 mgÆmL
)1 in 100 mM Hepes, pH 8.5, 150 mM KCl and 5 mM
MgCl2, with either 5 mM ADP-Mg
2+ or AMPPNP-Mg
2. For yeast
Hsp90 and Hsp90b reactions, 7.5 and 3.75 M excesses of DMS,
respectively, were used relative to the molar concentration of
Hsp90 lysine amino acid residues. Cross-linked dimer formation is
enhanced in the presence of AMPPNP for both yeast and human
Hsp90. In particular, cross-linking in the presence of AMPPNP gen-
erates a slowly migrating cross-linked species (shown by the top-
most arrow) that is most likely formed from N-terminal dimers of
the proteins. However, the amino acid residues that were cross-
linked in the ADP experiment are close enough in the AMPPNP
state to be subject to cross-linking. Formation of this slowly migrat-
ing band (shown by the slanted arrow) is inhibited by geldanamycin,
even when AMPPNP is present, producing a cross-linking pattern
similar to that with ADP.
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Hsp90b, which shows enhanced formation of this
slowly migrating band (see Results below), we demon-
strated that geldanamycin, and indeed ADP, both
severely inhibit formation of the slowest migrating
cross-linked species relative to AMPPNP, in common
with the results for yeast Hsp90 (Fig. 5D and Fig. S1).
ATP-lid and N-terminal dimerization mutations
modulate the degree of cross-linking of
human Hsp90
Mutations that affect either the conformation of the
ATP lid or block dimerization directly are expected to
affect the degree of cross-linking by inhibiting AMP-
PNP-induced N-terminal dimerization. We have previ-
ously shown that the ATP-lid mutation of yeast
Hsp90, T101I, inhibits N-terminal dimerization and
therefore the formation of cross-linked dimers, whereas
A107N promotes dimerization and cross-linking [10].
The results in Fig. 6A and Fig. S2 show that the yeast
Hsp90 mutation L15R inhibits cross-linking, as
expected, and suggest that this mutation acts by
directly preventing N-terminal dimerization. Likewise,
the equivalent mutation, L24R, as well as the T110I
mutation (yeast T101I), of human Hsp90 inhibited
cross-linking, while the A116N mutation (yeast
A107N) promoted it, as expected (Fig. 6B and
Fig. S1). These differences in cross-linking are particu-
larly apparent by the extent of formation of the slow-
est migrating cross-linked species, which was inhibited
by ADP and geldanamycin (or enhanced by AMP-
PNP) (Fig. 5A–D and Fig. S1). This species is most
likely formed as a result of cross-linking of the protein
in an N-terminally dimerized state. Thus, for muta-
tions inhibiting N-terminal dimerization, the bulk of
the cross-linked products appear to migrate at a lower
position than the products from mutations that pro-
mote N-terminal dimerization (compare A116N, T110I
and L24R in Fig. 6B and Fig. S2). However, in order
to verify this result, we decided to investigate the abil-
ity of the L24R mutation, which appears to prevent
N-terminal dimerization, to disrupt formation of the
slowly migrating cross-linked product observed for the
A116N mutant. The results in Fig. 6C and Fig. S2
show that the combination of the L24R and A116N
mutations clearly disrupts formation of this cross-
linked product and validates the conclusions drawn
from the results shown in Fig. 6B and Fig. S2. This
is also consistent with the dependency of the ATPase
activity of A116N on the L24R mutation in heterodi-
mer experiments. Collectively, the results show that
the effects caused by these mutations on ATPase
activity and N-terminal dimerization are the same for
both the human and yeast Hsp90s, and support the
view that human Hsp90 ATPase activity is also sub-
ject to ATP-coupled N-terminal dimerization.
Discussion
In yeast, the rate-limiting step for ATP turnover
appears to involve a complex series of structural rear-
rangements that lead to formation of a catalytically
active unit that is able to hydrolyse ATP [11], and
mutations (T22I, T101I and A107N) that affect forma-
tion of the catalytically active state have been
described [10]. In this study, we show that a C-termi-
nally truncated Hsp90b, which contains all the cata-
lytic machinery required for hydrolysis of ATP, and
mutants with alterations that inhibit conformational
changes in the ATP lid or prevent dimerization directly
all show low ATPase activity, as expected if the mode
for hydrolysis of ATP is based on the known mecha-
nism for yeast Hsp90 [9]. These same mutations also
inhibit the formation of cross-linked products that are
favourably formed in the presence of AMPPNP, but
whose formation is inhibited by ADP and geldanamy-
cin. The results collectively suggest a common mecha-
nism for hydrolysis of ATP by yeast and human
Hsp90. Furthermore, our results suggest that the
ATPase activity of each Hsp90b monomer is depen-
dent on the adjacent monomer. This implies that each
monomer must interact with its partner monomer, and
is strong evidence for N-terminal dimerization in
Hsp90b. This was further supported by ﬂuorescence
studies showing that AMPPNP promotes a closer asso-
ciation of the N-terminal domains of human Hsp90
than ADP. Consequently, our results, together with
the highly conserved amino acid sequence similarity
between the yeast and human Hsp90b N-terminal
domains, lead us to conclude that hydrolysis of
ATP by yeast and human Hsp90 shares a common
mechanism.
Although both yeast and human Hsp90 appear to
utilize ATP via the same mechanism, their activity is
not identical. In this study, the kcat values were esti-
mated as 0.91 and 0.056⁄min for yeast and human
Hsp90b, respectively, at 37  C. The lower activity seen
for the human protein suggests that N-terminal dimer-
ization, the rate-limiting step of ATP hydrolysis, is
slower in human Hsp90b. Thus a larger energy barrier
exists for formation of a stable N-terminally dimerized
state in Hsp90b. It would appear that binding of ATP
to Hsp90, although promoting N-terminal dimeriza-
tion, is not the only determining factor that governs
the stability of the closed state. This is not surprising
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number of conformational changes within Hsp90, such
as release of the catalytic loop from its middle domain
[9,17]. These additional structural changes allow the
ATPase activity of Hsp90 to be regulated not only by
the availability of ATP, but by co-chaperones that
affect parts of Hsp90 that are critical for formation of
a catalytic state. This has been clearly demonstrated in
structural studies that have shown how the co-chaper-
ones Aha1 and p23⁄Sba1 regulate the ATPase activity
of Hsp90 [9,17]. Indeed, by such mechanisms, the
ATPase activity of Hsp90 may also be inﬂuenced by
the nature of the client protein in the Hsp90 complex.
In fact, such co-chaperone interactions, which appear
to be similar for both the yeast and human Hsp90 pro-
teins, provide further evidence in support that the
human and yeast mechanisms are similar. For exam-
ple, we have shown that yeast Aha1 can stimulate the
ATPase activity of both yeast and human Hsp90s
[11,18,19], while Sba1, which is known to bind to the
closed state of yeast Hsp90, inhibits the ATPase activ-
ity of the human and yeast proteins [9,19,20]. Further-
more, Sti1 can inhibit the ATPase activity of both
yeast and human Hsp90s [11,18,19], and yeast and
human Cdc37 inhibit the ATPase activity of yeast
Hsp90 [9–12].
During the course of this work, it was shown that the
ATPase activity detected in human Hsp90b heterodimer
experiments using one intact monomer and another
monomer lacking the N-terminal domain was reduced
[21]. This suggested that the monomers of Hsp90b are
dependent on each other for the hydrolysis of ATP.
This is in full agreement with our experiments in which
we produced subtle mutations in residues of the N-ter-
minal domain of human Hsp90b that are known to be
involved in N-terminal dimerization of yeast Hsp90,
and performed heterodimer experiments with these
mutants (T110I or L24R) and wild-type Hsp90b that
resulted in reduced ATPase activity. Richter et al. [21]
also showed that bound ATP remains solvent-accessi-
ble, and concluded either that the closed state does not
exist or that it is less populated relative to the open
state. Our results suggest that a closed state is formed,
but is either less stable or is formed less readily than
observed for the yeast protein. This difference in the
ability of human and yeast to form a catalytically active
closed state is reﬂected in their ATPase activity, which
is 16 times lower for Hsp90b (kcat for yeast =
0.91⁄min, kcat for Hsp90b = 0.056⁄min at 37  C).
During the preparation of this manuscript, evidence
suggesting that constitutively expressed yeast Hsc90
hydrolyses ATP in an independent manner, not utiliz-
ing N-terminal dimerization, was published [22]. In
these experiments, an inactive E33A mutant was mixed
with and had no effect on wild-type Hsc90 ATPase
activity. It was therefore concluded that the two halves
of the dimer act independently to hydrolyse ATP.
However, as the E33A mutant is fully able to bind
ATP, it might still be subject to ATP-lid closure, thus
providing a platform with which the adjacent active
monomer can N-terminally dimerize. Following hydro-
lysis by the wild-type monomer, it might then disen-
gage from the closed E33A monomer and enter a
second round of ATP hydrolysis. In contrast, the
L24R mutant in our model prevents N-terminal dimer-
ization and reduces the ATPase activity of the A116N
mutant, thus suggesting a dependent mechanism based
on N-terminal dimerization.
Whether the 94 kDa glucose-regulated Hsp90 of the
endoplasmic reticulum, Grp94, can hydrolyze ATP has
also been very controversial. Amino acid sequence
analysis suggests that Grp94 should be able to hydro-
lyse ATP, but this activity has not been identiﬁed.
However, ATPase activity for canine Grp94 has
recently been detected, although the activities reported,
kcat = 0.02⁄min at 37  C and 0.36⁄min at 25  C, vary
[23,24]. ATPase activity has also been reported for
the mitochondrial Hsp90 TRAP1 (kcat = 0.1⁄min at
30  C and 0.16⁄min at 25  C [25,26]), as well for
Escherichia coli high temperature protein G (HTPG)
(kcat = 0.16⁄min at 37  C [6]). In conclusion, our
results suggest that eukaryotic Hsp90s, and perhaps all
types of Hsp90, utilize ATP via the same structural
mechanism, and that differences in the level of activity
are due to varying stability of the N-terminally dimer-
ized state induced through ATP binding.
Experimental procedures
Protein production and Hsp90 ATPase activity
assays
Expression and puriﬁcation of the His-tagged yeast Hsp90
and human Hsp90b, including mutant forms, was per-
formed as previously described [11,18,19]. C-terminally
truncated His-PreScission-Hsp90b (N615, amino acid resi-
dues 1–615) was cloned into pTwoE (pET-17b engineered
to contain a His tag and a PreScission cleavage site; per-
sonal communication, A. W. Oliver, Institute of Cancer
Research, London, UK) as an NheI–SpeI DNA fragment,
and expressed and puriﬁed as for the Hsp90b protein. Puri-
ﬁed proteins were dialysed against 20 mm Tris⁄HCl,
pH 7.5, containing 1 mm EDTA and 1 mm dithiothreitol,
and then concentrated using Vivaspin concentrators (Sarto-
rius, Epsom, UK) with an appropriate molecular mass
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described [18,19] using 2 lm yeast or 2–20 lm human
Hsp90 depending on activity. All samples were assayed at
least three times, and some up to 12 times. For Hsp90 hete-
rodimer formation, the Hsp90 isoforms were mixed in a
ratio of 1 : 1 (2 lm A116N:2 lm T110I or L24R), 1 : 5
(2 lm A116N:10 lm T110I or L24R) or 1 : 10 (2 lm
A116N:20 lm T110I; 2 lm A116N:20 lm Hsp90b and 2 lm
A116N:20 lm yeast Hsp90), and incubated for 60 min prior
to the assay. For heterodimer experiments, the total activity
for each Hsp90 construct was determined separately and
then in combination. The kcat values for the yeast, human
Hsp90b and A116N mutant proteins were 0.91, 0.056 and
0.24⁄min at 37  C, respectively. Non-speciﬁc ATPase
activity was determined by the addition of 30–60 lm geld-
anamycin.
Mutagenesis
Single amino acid changes in yeast Hsp90 and human
Hsp90b were generated using the QuickChange mutagenesis
system (Stratagene, La Jolla, CA, USA) as previously
described [10]. The following mutations were introduced:
L15A, L15R, L18A and L18R for yeast Hsp90, and T31I,
T110I, A116N, L24A, L24R, L27A, L27R, L24R-A116N,
A116N-C366A and E20C-C366A-A116N for human
Hsp90b. Mutations were conﬁrmed by dye-terminator
sequencing.
Cross-linking
Proteins for cross-linking were diluted to a ﬁnal concentra-
tion of 0.25–0.5 mgÆmL
)1 in 100 mm Hepes, pH 8.5,
150 mm KCl and 5 mm MgCl2. Either 5 mm ADP-Mg
2+
or 5 mm AMPPNP-Mg
2+ was added to the diluted protein.
Cross-linking reactions were then carried out as described
previously [10]. For yeast Hsp90 and Hsp90b reactions, 7.5
and 3.75 molar excesses of DMS, respectively, were used
relative to the molar concentration of Hsp90 lysine amino
acid residues. Reactions of 20 lL were incubated for either
15 or 60 min at room temperature. Reactions were stopped
by the addition of 1 lL Tris, pH 6.8, and SDS loading buf-
fer. Samples were analysed by 4–12% SDS–PAGE and
stained with Coomassie blue.
Fluorescent labelling and excimer formation
Fluorescent labelling was carried out as described previ-
ously [10]. Brieﬂy, proteins for labelling were desalted in
100 mm Hepes, pH 8.0, containing 150 mm KCl. Triplicate
samples of each protein were then diluted to 10 mgÆmL
)1,
and the non-thiol reducing agent Tris(2-carboxyethyl)-
phosphine was added to a ﬁnal concentration of 10 mm.
Subsequently, 10 mm N-(1-pyrene)-maleimide (in 100%
dimethylformamide; Sigma-Aldrich, Poole, UK) was
added, and the reaction was incubated at room tempera-
ture for 60 min. The reaction was then desalted twice into
20 mm Tris, pH 7.5, containing 1 mm EDTA. Fluores-
cence measurements were carried out at 10 lm protein
concentration in 20 mm Tris, pH 7.4, 12 mm MgCl2,
150 mm KCl and either 10 mm ADP or AMPPNP. For
heterodimer experiments, 5 lm of pyrene-labelled E20C-
C366A-A116N mutant was mixed with control protein
(C366A-A116N, pyrene treated but not labelled at posi-
tion 20) in ratios of 1 : 1 and 1 : 3, respectively. Labelled
proteins were excited at 341 nm and emission spectra
obtained from 220 to 600 nm using a Cray Eclipse ﬂuores-
cent spectrophotometer (Varian, Inc., Palo Alto, CA,
USA). Normalized spectra of ADP-containing experi-
ments were subtracted from normalized spectra from
AMPPNP-containing experiments, and the resultant data
were plotted.
Isothermal titration calorimetry and Kd
determinations
The heat of interaction was measured on an MSC system
(Microcal Europe, Milton Keynes, UK), with a cell volume
of 1.458 mL, under the same buffer conditions (20 mm Tris,
pH 8.0, containing 1 mm EDTA and 5 mm NaCl) at 30  C.
Twenty 13.5 lL aliquots of 1 mm AMPPNP were injected
into 50 lm of human or yeast Hsp90 or the L15R mutant
or 24.3 lm L24R mutant. Heats of dilution were deter-
mined in a separate experiment by diluting protein into buf-
fer, and the corrected data were ﬁtted using a non-linear
least-squares curve-ﬁtting algorithm (Microcal Origin) with
three ﬂoating variables: stoichiometry (ﬁxed at 1.0), binding
constant and change in enthalpy of interaction.
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